Raymond James Initiates Coverage On MapLight Therapeutics with Strong Buy Rating, Announces Price Target of $46
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsInitiationPrice Target
Raymond James analyst Tiago Fauth initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Strong Buy rating and announces Price Target of $46.
Raymond James analyst Tiago Fauth initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Strong Buy rating and announces Price Target of $46.